CA2655094C - Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression - Google Patents

Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression Download PDF

Info

Publication number
CA2655094C
CA2655094C CA2655094A CA2655094A CA2655094C CA 2655094 C CA2655094 C CA 2655094C CA 2655094 A CA2655094 A CA 2655094A CA 2655094 A CA2655094 A CA 2655094A CA 2655094 C CA2655094 C CA 2655094C
Authority
CA
Canada
Prior art keywords
cannabigerol
intra
isolated
depression
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2655094A
Other languages
English (en)
French (fr)
Other versions
CA2655094A1 (en
Inventor
Richard Musty
Richard Deyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of CA2655094A1 publication Critical patent/CA2655094A1/en
Application granted granted Critical
Publication of CA2655094C publication Critical patent/CA2655094C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2655094A 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression Active CA2655094C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81381406P 2006-06-15 2006-06-15
US60/813,814 2006-06-15
PCT/GB2007/002216 WO2007144628A1 (en) 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression

Publications (2)

Publication Number Publication Date
CA2655094A1 CA2655094A1 (en) 2007-12-21
CA2655094C true CA2655094C (en) 2014-09-30

Family

ID=38353631

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2655094A Active CA2655094C (en) 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression

Country Status (5)

Country Link
US (2) US8481085B2 (https=)
EP (1) EP2037901B1 (https=)
JP (1) JP5286255B2 (https=)
CA (1) CA2655094C (https=)
WO (1) WO2007144628A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2471190T3 (es) * 2003-06-24 2014-06-25 Gw Pharma Limited Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US20100293021A1 (en) * 2009-01-23 2010-11-18 Intranet Productivity Solutions, Ltd. Method and system for task tracking and allocation
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US10045540B2 (en) 2014-04-01 2018-08-14 Fayetteville State University Pest control composition
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3576724B1 (en) 2017-02-01 2023-09-27 GBS Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
CA3085007C (en) * 2017-12-08 2021-12-21 Biotech Institute LLC High cannabigerol cannabis plants, methods of producing and methods of using them
EP3745884A1 (en) * 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CN112969452A (zh) 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
IL326299A (en) * 2018-10-31 2026-04-01 Baymedica Inc Cannabinoid analogs and methods for their preparation
CA3129535A1 (en) 2019-03-07 2020-09-10 Oludare ODUMOSU Formulations for treating cluster symptoms associated with autism spectrum disorder
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
JP2022551476A (ja) * 2019-10-08 2022-12-09 ベッソール ファルマ、エルエルシー カンナビノイド及びカンナビノイド酸の製造プロセス
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
EP4065554A4 (en) * 2019-11-26 2024-01-10 Canopy Growth Corporation CANNABIGEROL DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS
JP2023503330A (ja) * 2019-11-26 2023-01-27 キャノピー グロウス コーポレイション カンナビノイド誘導体
WO2021113958A1 (en) * 2019-12-09 2021-06-17 Canopy Growth Corporation Cannabinoid derivatives
US11767306B2 (en) 2020-01-17 2023-09-26 Cannacraft, Inc Methods for converting CBD to tetrahydrocannabinols
EP4121164A1 (en) * 2020-03-17 2023-01-25 Tauriga Sciences Inc. Medicated cannabinoid compositions, methods of manufacturing, and methods of treatment
US11786838B2 (en) * 2020-03-23 2023-10-17 Cannacraft, Inc. Methods for removing pesticides from Cannabis products
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
WO2022147270A1 (en) 2020-12-31 2022-07-07 Cookies Creative Consulting & Promotions, Inc. Compositions comprising cannabis and mushroom extracts, and uses thereof
US11465957B1 (en) 2021-04-08 2022-10-11 MYKU Biosciences LLC Methods and systems for crystallizing and isolating individual cannabinoids
US11345650B1 (en) 2021-04-08 2022-05-31 MYKU Biosciences LLC Methods and systems for crystallizing and isolating individual cannabinoids
CN115504862B (zh) * 2021-06-07 2024-07-05 南通新世元生物科技有限公司 一种大麻萜酚的制备方法
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same
WO2024015780A1 (en) 2022-07-11 2024-01-18 Ilera Therapeutics Llc Zlt-007 and methods of treating diabetic neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002056932A2 (en) * 2000-10-27 2002-07-25 Emlin Biosciences Thermal vaporizing device for drug delivery
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
AU2003240824B9 (en) * 2002-05-31 2008-09-25 University Of Mississippi Transmucosal delivery of cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
ES2471190T3 (es) 2003-06-24 2014-06-25 Gw Pharma Limited Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno

Also Published As

Publication number Publication date
EP2037901A1 (en) 2009-03-25
CA2655094A1 (en) 2007-12-21
US20080031977A1 (en) 2008-02-07
US20140039043A1 (en) 2014-02-06
JP2009539961A (ja) 2009-11-19
JP5286255B2 (ja) 2013-09-11
WO2007144628A1 (en) 2007-12-21
EP2037901B1 (en) 2014-01-08
US8481085B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
CA2655094C (en) Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression
CA3158059A1 (en) Tryptamine compositions for enhancing neurite outgrowth
US20100292345A1 (en) Therapeutic uses of cannabigerol
CA2653835A1 (en) New use for cannabinoid
US11672761B2 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
GB2602019A (en) Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
EP2760440A1 (en) A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)
US20140377382A1 (en) Cannabinoid-containing plant extracts as neuroprotective agents
US20200163931A1 (en) Oral composition of extracted cannabinoids and methods of use thereof
KR20230121776A (ko) 아마니타 무스카리아 화합물
US12357585B2 (en) Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
Wen et al. A review of nardosinone for pharmacological activities
EP1644349B1 (en) Pharmaceutical compositions comprising cabbinochreme type compounds
AU2011284357B2 (en) A method of managing broncho-constrictive condition
Williams et al. Cannabinoids‐human physiology and agronomic principles for production
Das et al. Agarwood as a neuroprotective agent: a comprehensive review of existing evidence and potential avenues for future research
HK1084670B (en) Pharmaceutical compositions comprising cabbinochreme type compounds
US20220296522A1 (en) Bryoid compositions, methods of making and use thereof
US12564599B2 (en) Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
TW201309289A (zh) 控制支氣管收縮病狀之方法

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240823

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20250227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250320

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423